UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
Specialized Disclosure Report
Medtronic plc
(Exact name of Registrant as Specified in its Charter)
| | | | | | | | | | | | | | |
| | | | |
| Ireland | | 1-36820 | | 98-1183488 |
(State or other jurisdiction
of incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
| | | | | | | | |
| | |
20 On Hatch, Lower Hatch Street
Dublin 2, Ireland | | n/a |
| (Address of principal executive offices) | | (Zip Code) |
| | | | | | | | |
| | |
| Karen Parkhill | | 763-514-4000 |
(Name and telephone number, including area code, of the person to contact in connection with this report.)
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
| | | | | |
| x | Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2022. |
INFORMATION TO BE INCLUDED IN THE REPORT
Section 1 - Conflict Minerals Disclosure
Item 1.01 Conflict Minerals Disclosure and Report
This Form SD of Medtronic plc (the “Company”) is filed pursuant to Rule 13p-1 (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2022 to December 31, 2022.
A copy of Company’s Conflict Minerals Report is provided as Exhibit 1.01 hereto and details the due diligence measures undertaken during the reporting period by the Company on a consolidated basis. A copy of the Conflict Minerals Report is also publicly available through the Company’s website: www.medtronic.com (under the “Our Company” caption and “Financials” subcaption).
Item 1.02 Exhibit
The Company has filed, as an exhibit to this Form SD, the Conflict Minerals Report of the Company required by Item 1.01.
Section 2 - Exhibits
Item 2.01 Exhibits
The following exhibit is filed as part of this report:
Exhibit 1.01 - Conflict Minerals Report of the Company
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
| | | | | | | | | | | |
| | | Medtronic plc |
| | | |
| Date: May 30, 2023 | | By | /s/ Karen L. Parkhill |
| | | Karen L. Parkhill |
| | | Executive Vice President and Chief Financial Officer |
EXHIBIT INDEX
Medtronic plc
Form SD
